Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with disease at least 3 months before study~* Muscle weakness~* Received corticosteroids with or with out disease modifying antirheumatic drugs at least 3 months before study however not responding to this therapy~Exclusion Criteria:~* Other idiopathic inflammatory myopathies~* Myopathy other than polymyositis and dermatomyositis~* Patients with late stages of disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- BAF312 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).